Early clinical studies highlighted nonhormonal male contraception candidates YCT-529 and ADAM. YCT-529 showed favorable phase 1a safety, while ADAM reported mild transient effects and durability up to 24 months.
South Korean pharmaceutical companies are expanding digital healthcare businesses as they seek new revenue sources. The domestic market recorded 7.7409 trillion won in sales in 2024, while companies including Daewoong Pharmaceutical, Dong-A ST, Handok and Yuhan are advancing products and investments.
Wearable technologies are transforming clinical trials and healthcare with continuous monitoring capabilities, though clinical validation remains limited. While ECG features provide useful data for cardiac monitoring, many wearable metrics lack clinical accuracy and can cause patient anxiety. The technology shows promise for activity tracking and specific medical applications but requires cautious interpretation.
Recent research shows younger heart disease patients face unique parenting challenges, middle-aged healthy eating protects against cognitive decline, and timing evening meals three hours before bed improves cardiovascular markers.
A phase IIa clinical trial found that a single intravenous dose of dimethyltryptamine (DMT) with psychological support rapidly reduced depressive symptoms in 34 adults with major depressive disorder, with improvements sustained for up to three months.
